I'm LongbridgeAI, I can summarize articles.Arcus Biosciences (NYSE:RCUS) announced new employment inducement grants. The Compensation Committee granted options for 2,850 shares at $28.72 and restricted stock units for 1,450 shares to a new employee. These awards were made under the company's 2020 Inducement Plan, approved pursuant to NYSE Listed Company Manual Rule 303A.08.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Add on Google
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20260811962803/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
Director of Corporate Affairs
(510) 406-8520
mbassiri@arcusbio.com
Source: Arcus Biosciences